A selective ALK inhibitor in ALK-rearranged patients

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages 564-565

  Yang, James Chih Hsin ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CH 5424802; CRIZOTINIB; DOCETAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALK GENE; BRAIN METASTASIS; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; DRUG DOSE ESCALATION; EDEMA; EML4 ALK ONCOGENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VISUAL DISORDER;

ADENOCARCINOMA; CARBAZOLES; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84878348650     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70170-0     Document Type: Letter

References (10)

1. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
3. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
4. Shaw AT, Kim DW, Nakagawa K, Seto T Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). Ann Oncol 2012, Abstr LBA1_PR.
5. Shaw AT, Engelman JA ALK in lung cancer: past, present, and future. J Clin Oncol 2013, 31:1105-1111.
6. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
7. Kinoshita K, Asoh K, Furuichi N, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 2012, 20:1271-1280.
8. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer cell 2011, 19:679-690.
9. Seto T, Kiura K, Nishio M, Nakagawa K CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, published online April 30. http://dx.doi.org/10.1016/S1470-2045(13)70142-6.
10. Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013, published online March 26. 10.1158/2159-8290.cd-12-0440.